Table 1.
Clinicopathological characteristics and Tumor Regression Grade.
| Variable | No | Total or Partial Tumor Regression 25 Patients (42.3) |
Stable or Progressive Disease 34 Patients (57.6) |
p Value * |
|---|---|---|---|---|
| Age (years) † | 0.5753 | |||
| <63 | 32 (54.7) | 12 (37.5) | 20 (62.5) | |
| >63 | 27 (45.3) | 13 (48.2) | 14 (51.8) | |
| Gender | 0.5190 | |||
| Male | 41 (69.4) | 19 (46.3) | 22 (53.7) | |
| Female | 18 (30.6) | 6 (33.3) | 12 (66.4) | |
| Tumor Site | 0.0108 ‡ | |||
| Upper third | 25 (42.3) | 15 (60.0) | 10 (40.0) | |
| Middle third | 8 (13.5) | 3 (37.5) | 5 (62.5) | |
| Antrum | 18 (30.5) | 6 (33.3) | 12 (66.4) | |
| All | 8 (13.7) | 1 (12.5) | 7 (87.5) | |
| Serum CEA Levels (ng/mL) | 0.0519 | |||
| <3.5 | 43 (72.8) | 22 (51.2) | 21 (48.8) | |
| >3.5 | 16 (27.2) | 3 (18.7) | 13 (81.3) | |
| Serum Ca19-9 Levels (ng/mL) | 0.3751 | |||
| <37 | 45 (76.3) | 21 (46.6) | 24 (53.4) | |
| >37 | 14 (23.7) | 4 (28.5) | 10 (71.5) | |
| Performance Status | 0.7334 | |||
| 0 | 22 (37.3) | 12 (54.5) | 10 (45.5) | |
| 1 | 27 (45.8) | 7 (25.9) | 20 (74.1) | |
| 2 | 10 (16.9) | 6 (60.0) | 4 (40.0) | |
| Tumor Depth | 0.0052 ‡ | |||
| T1 | 2 (3.4) | 2 (100.0) | 0 (0.0) | |
| T2 | 5 (8.4) | 3 (60.0) | 2 (40.0) | |
| T3 | 25 (42.5) | 14 (56.0) | 11 (44.0) | |
| T4a | 19 (32.2) | 4 (21.1) | 15 (78.9) | |
| T4b | 8 (13.5) | 2 (25.0) | 6 (75.0) | |
| Node Metastasis | 0.0373 ‡ | |||
| No | 25 (42.3) | 15 (60.0) | 10 (40.0) | |
| Yes | 34 (57.7) | 10 (29.5) | 24 (70.5) | |
| Macroscopic Type | 0.0010 ‡ | |||
| 1 | 17 (28.8) | 13 (76.5) | 4 (23.5) | |
| 2 | 18 (30.5) | 6 (33.4) | 12 (66.6) | |
| 3 | 14 (23.8) | 5 (35.7) | 9 (64.3) | |
| 4 | 10 (16.9) | 1 (10.0) | 9 (90.0) | |
| Lauren’s Classification | 0.0089 ‡ | |||
| Intestinal | 25 (42.4) | 16 (64.0) | 9 (36.0) | |
| Diffuse/Mixed | 34 (57.6) | 9 (26.5) | 25 (73.5) | |
| Histological Grade | 0.0002 ‡ | |||
| Well Diff. | 11 (18.7) | 9 (81.8) | 2 (18.2) | |
| Mod. Diff. | 8 (13.6) | 6 (75.0) | 2 (25.0) | |
| Poor Diff. | 40 (67.7) | 10 (25.0) | 30 (75.0) | |
| Tumor Size † | 0.0001 ‡ | |||
| <3 cm | 29 (49.1) | 20 (68.9) | 9 (31.1) | |
| >3 cm | 30 (50.9) | 5 (16.6) | 25 (83.4) | |
| NPS Score | 0.0001 ‡ | |||
| 0 | 6 (10.2) | 6 (100.0) | 0 (0.0) | |
| 1 | 18 (30.5) | 11 (61.2) | 7 (38.8) | |
| 2 | 12 (20.4) | 4 (33.4) | 8 (66.6) | |
| 3 | 13 (22.1) | 3 (23.0) | 10 (77.0) | |
| 4 | 10 (16.8) | 1 (10.0) | 9 (90.0) | |
| NPS Group | 0.0001 ‡ | |||
| 0 | 6 (10.2) | 6 (100.0) | 0 (0.0) | |
| 1 | 30 (50.9) | 15 (50.0) | 15 (50.0) | |
| 2 | 23 (38.9) | 4 (17.4) | 19 (82.6) |
Numbers in parentheses are percentages. CEA indicates carcinoembryonic antigen (normal value: 3.5 ng/mL); Ca19-9 indicates carbohydrate antigen (normal value: 37 ng/mL); Performance status according to the ECOG scale; * χ2 test; † age and tumor size were dichotomized by median values; ‡ significant value.